Serum Albumins How Useful as a Predictor of Operatlwe Risk?

摘要

These recommendations misquote Dr Iseman's article. Latent tuberculosis is treated with isoniazidfor 6 to 9 months or rifampin for 4 months, not both. There is a promising study of short-course combination (isoniazid plus rifap-entine) therapy that is not yet published. The current standard is monother-apy. Compared to isoniazid, rifampin has advantages (shorter duration, less hepatotoxicity, lower frequency of resistance) and disadvantages (more drug interactions, other toxicities, higher cost and, most important, the risk of inducing rifampin resistance if active disease develops during treatment). Combination therapy is generally reserved for active tuberculosis. With respect to Quantiferon testing, to quote Dr Iseman, "the value of IGRAs over the TST is not fully delineated."1 Most of the studies have looked at its performance in active tuberculosis, not its ability to predict who will develop reactivation disease. The optimal testing strategy remains an solved issue.